ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1497

Eltrombopag in SLE-Associated Thrombocytopenia: Treatment Response and Thrombotic Complications

Asmaa Beltagy1, Abeer Abdelati1, Fatma Fayed2, Nouran Eshak3, Ashraf Elghandour1 and Mohamed Halaby4, 1Faculty of Medicine, Alexandria University, Alexandria, Egypt, 2Alexandria University Student Hospital, Alexandria, Egypt, 3Mayo Clinic Arizona, Lubbock, TX, 4Faculty of Medicine, Alexandria University, Birmingham, AL

Meeting: ACR Convergence 2023

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1488–1512) SLE – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: This study aimed to assess the efficacy of Eltrombopag, a medication used to treat thrombocytopenia, in patients with systemic lupus erythematosus (SLE)-associated thrombocytopenia. Additionally, we investigated the occurrence of thrombotic complications in these patients.

Methods: Nineteen SLE patients with thrombocytopenia were followed for two years or until Eltrombopag discontinuation. Data included medical history, examinations, labs, antiphospholipid serology, response rates, and complications

Results: All patients (12 females, mean age 33±12 years) fulfilled the SLICC criteria for SLE and presented with mucocutaneous bleeding. Antiphospholipid serology was positive in 11 patients, with two patients meeting the criteria for antiphospholipid syndrome due to a history of deep vein thrombosis. Six patients had a history of lupus nephritis. Eltrombopag was initiated after the failure of prior therapies. At the start of treatment, the mean platelet count was 12±13 x 109. A daily dose of 50mg of Eltrombopag was used, with one patient requiring 75mg. Twelve patients demonstrated a sustained response, and four patients were able to taper off corticosteroids. However, one patient did not respond to Eltrombopag. Six patients developed thrombotic complications, including deep vein thrombosis, pulmonary embolism, myocardial infarction, cavernous sinus thrombosis, stroke, and catastrophic antiphospholipid syndrome. The median time to thrombotic events was 5.5 months (range: 0.3-8) with a median platelet count of 170 x 109 (range: 68-330). These complications necessitated the discontinuation of Eltrombopag. Four out of the six patients with thrombotic events had positive antiphospholipid antibodies, and two had a history of lupus nephritis.

Conclusion: Our study demonstrates that Eltrombopag is effective in treating SLE-associated thrombocytopenia, with favorable treatment responses observed in the majority of patients, including steroid tapering. However, caution should be exercised regarding the development of thrombotic complications, especially in patients with positive antiphospholipid antibodies. Further research is warranted to identify risk factors and strategies for preventing these complications in this patient population.

Supporting image 1


Disclosures: A. Beltagy: None; A. Abdelati: None; F. Fayed: None; N. Eshak: None; A. Elghandour: None; M. Halaby: None.

To cite this abstract in AMA style:

Beltagy A, Abdelati A, Fayed F, Eshak N, Elghandour A, Halaby M. Eltrombopag in SLE-Associated Thrombocytopenia: Treatment Response and Thrombotic Complications [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/eltrombopag-in-sle-associated-thrombocytopenia-treatment-response-and-thrombotic-complications/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/eltrombopag-in-sle-associated-thrombocytopenia-treatment-response-and-thrombotic-complications/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology